octreotide acetate

P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=332, Active, not recruiting, Camurus AB | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=20, Active, not recruiting, Debiopharm International SA | N=30 --> 20

P2, N=90, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting

Therefore, an individual approach is necessary in the treatment of patients with acromegaly, based on repeated insight to their clinical, biochemical, pathological and imaging characteristics. In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB).

P4, N=21, Completed, Columbia University | Unknown status --> Completed

P3, N=196, Active, not recruiting, Sinotau Pharmaceutical Group | Recruiting --> Active, not recruiting

P2, N=90, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Subsequently, sandostatin LAR (30 mg per week) was used as systemic therapy. He had no recurrence or metastasis for 6-month follow-up. Thus, acute chest pain can be the first manifestation of MEN1-associated NEN, and comprehensive treatment including surgery, radiation and systemic treatment may be an effective strategy for MEN1-associated NEN.

First-line 177Lu-Dotatate plus octreotide LAR significantly extended median progression-free survival (by 14 months) in patients with grade 2 or 3 advanced gastroenteropancreatic neuroendocrine tumours. 177Lu-Dotatate should be considered a new standard of care in first-line therapy in this population.

P3, N=288, Active, not recruiting, RayzeBio, Inc. | Recruiting --> Active, not recruiting

P2, N=135, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC

P=N/A, N=70, Recruiting, Mario Negri Institute for Pharmacological Research | Not yet recruiting --> Recruiting

P3, N=427, Active, not recruiting, National Cancer Institute (NCI)

P3, N=332, Active, not recruiting, Camurus AB | Recruiting --> Active, not recruiting

This is the first trial investigating the efficacy of CAM2029 versus SoC SRL therapy using a head-to-head, superiority trial design. It is expected to be the first trial to investigate the efficacy of increased dosing frequency of a high-exposure SRL. A BIRC will limit bias and measurement variability and ensure high-quality efficacy data. Additionally, inclusion of patients with well-differentiated Grade 3 NET may elucidate treatment strategies for this rarely investigated patient population.

The long-acting SSAs octreotide long-acting release and lanreotide are commonly used in the first-line metastatic setting because of their tolerable side effect profile...A key question in management of patients with gastroenteropancreatic and lung NETs is the sequencing of Lu-DOTATATE in relation to other systemic treatments (such as everolimus) or liver-directed therapies. This question is particularly complicated given the heterogeneity of NETs and the near absence of randomized trials comparing active treatment options. This state-of-the-art review examines the evidence supporting use of somatostatin-receptor-targeted treatments within the larger landscape of NET therapy and offers insights regarding optimal patient selection, assessment of benefit versus risk, and treatment sequencing.

P=N/A, N=70, Not yet recruiting, Mario Negri Institute for Pharmacological Research

P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

P3, N=288, Recruiting, RayzeBio, Inc.

P1, N=30, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: May 2025 --> Nov 2024

P3, N=288, Recruiting, RayzeBio, Inc. | Phase classification: P1b --> P3

P3, N=222, Active, not recruiting, Advanced Accelerator Applications | Trial completion date: Jul 2027 --> Oct 2027

P=N/A, N=411, Completed, Changhai Hospital

Pancreatic neuroendocrine tumor could lead to malignant hypercalcemia; secretion of PTHrP is the most common cause, and signs and symptoms are usually milder than paraneoplastic syndrome due to hematologic and solid tumor. Generally, survival is better; however, its treatment is challenging, and primary debulking surgery is often required. A team approach to management is important at all points.

P1b, N=288, Recruiting, RayzeBio, Inc. | N=218 --> 288

Long-acting SSAs are an effective and safe initial therapy of patients with well differentiated NET, allowing tumor growth as well as symptoms control for long-time in selected patients.

After further oncology evaluation, long-acting octreotide acetate was initiated, and she continues close follow up...Fig 1c. Histology slide of rectal polyp 400x H&E showing uniform round nuclei with finely stippled “salt and pepper” chromatin consistent with NET.

P3, N=222, Active, not recruiting, Advanced Accelerator Applications | Trial primary completion date: Nov 2023 --> Jul 2023

Currently, the patient is treated with monthly octreotide LAR...She was initially treated with bromocriptine and then underwent TSS without achieving remission...Modern NGS-based genetic testing is an effective method for identifying such cases. Precise molecular testing has an impact on the timely diagnosis of these lesions, as well as on their prognosis and the need for genetic counseling.

Octreotide LAR dosing above the label-maximum dose is common and IR rescue dosing appears to be underutilized.

P3, N=220, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.

P1b, N=30, Recruiting, Debiopharm International SA | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> May 2025

P2, N=20, Completed, Assistance Publique Hopitaux De Marseille | Unknown status --> Completed

The questions regarded the use of long-acting octreotide and lanreotide in the following settings: functioning and non-functioning NET refractory to label dose, first-line metastatic pulmonary NET, combination with other therapy with an antiproliferative intent, maintenance in NET responding to other therapies, adjuvant treatment, Ki-67-related cut-off, somatostatin receptor imaging, safety, and feasibility...Mention of such specific issues by the main European guidelines (ENETS, European Neuroendocrine Tumor Society, and ESMO, European Society for Medical Oncology) was explored and their position reported. However, different clinical decisions on single patients could be made if the case is carefully discussed within a NET-dedicated multidisciplinary team.

Key inclusion criteria included a biochemical and clinical diagnosis of acromegaly due to a pituitary adenoma with persistent or recurrent disease, treatment with a stable dose of octreotide long-acting release or lanreotide Autogel for at least 3 months as monotherapy, and controlled disease with IGF-1 =1 x upper limit of normal (ULN). Key exclusion criteria included GH =2.5 µg/L at screening, pituitary surgery within 6 months of screening, prior pituitary irradiation, and recent treatment with pasireotide, pegvisomant, or dopamine agonists...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

First line medical therapy consists of first-generation injectable somatostatin receptor ligands (SRL) (octreotide LAR, lanreotide autogel)...If IGF-1 levels do not normalize, pasireotide or pegvisomant can be tried...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

Outcomes were: demographic characteristics; treatment frequency by line of treatment (LOT) and changes between LOTs (Sankey plot); treatment persistence for first LOT (LOT 1) monotherapies (Kaplan-Meier estimator); and treatment up-/downtitration (=30% dose change, evaluated for octreotide long-acting release [OCT] and lanreotide depot [LAN])...Other LOT 1 classes were DAs (cabergoline; 34.5%) and GHRAs (pegvisomant; 10.5%). Only 7 patients received second-generation SRL pasireotide and no patients received oral octreotide in LOT 1...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

Change to multiple small meals, addition of cornstarch to diet, continuous blood glucose monitoring (CGM), diazoxide (70 mg oral, three times a day), and monthly octreotide LAR (30 mg) has allowed the patient to avoid hypoglycemia... Our study highlights that in adults with non-insulinoma pancreatogenous hypoglycemia, genetic causes of HH should be considered in the differential diagnosis.*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference.

P1b, N=218, Recruiting, RayzeBio, Inc. | Active, not recruiting --> Recruiting